A Scott Mathis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/121500/publications.pdf

Version: 2024-02-01

840585 677027 29 468 11 22 citations h-index g-index papers 30 30 30 510 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Evaluation of the use of chlorpromazine for agitation in pediatric patients. Mental Health Clinician, 2021, 11, 40-44.	0.5	2
2	Adverse effect profile comparison of pain regimens with and without intravenous acetaminophen in total hip and knee arthroplasty patients. SAGE Open Medicine, 2017, 5, 205031211769914.	0.7	10
3	Managed care aspects of managing multiple sclerosis. American Journal of Managed Care, 2013, 19, S28-34.	0.8	1
4	Economic burden and current managed care challenges associated with hepatitis C. American Journal of Managed Care, 2012, 18, S350-9.	0.8	3
5	Documentation of Clinical Activities Using a Web-Based Application within an Eight Hospital Integrated Health Care System: A Six-Year Experience. Hospital Pharmacy, 2010, 45, 854-862.	0.4	O
6	Micronutrient-responsive cerebral dysfunction other than Wernicke's encephalopathy after malabsorptive surgery. Surgery for Obesity and Related Diseases, 2010, 6, 171-180.	1.0	13
7	Influenza Vaccination Among Medical Residents in a Teaching Hospital. Infection Control and Hospital Epidemiology, 2008, 29, 89-91.	1.0	11
8	Comparison of two instruments for assessing risk of postoperative nausea and vomiting. American Journal of Health-System Pharmacy, 2008, 65, 448-453.	0.5	8
9	Effects of 16-hour shifts on order-verification medication errors by hospital pharmacists. American Journal of Health-System Pharmacy, 2007, 64, 1467-1468.	0.5	2
10	Oral Ganciclovir Versus Low-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Recipients of Kidney and Pancreas Transplants. Transplantation, 2007, 83, 290-296.	0.5	41
11	The Pharmacodynamic Effects of Sirolimus and Sirolimus-Calcineurin Inhibitor Combinations on Macrophage Scavenger and Nuclear Hormone Receptors. Journal of Pharmaceutical Sciences, 2007, 96, 209-222.	1.6	21
12	Use of Filgrastim among Febrile Inpatients who Received Outpatient Filgrastim or Pegfilgrastim. Hospital Pharmacy, 2006, 41, 260-264.	0.4	1
13	Percutaneous Coronary Intervention–Related Bleeding Risk Factors in Current Practice. Annals of Pharmacotherapy, 2005, 39, 1627-1633.	0.9	10
14	Corticosteroids an important cause of hyperglycemia. American Journal of Health-System Pharmacy, 2005, 62, 1976-1979.	0.5	3
15	Venous Thromboembolism Prevention in Acutely III Nonsurgical Patients. Annals of Pharmacotherapy, 2005, 39, 1318-1324.	0.9	2
16	Drug-related dyslipidemia after renal transplantation. American Journal of Health-System Pharmacy, 2004, 61, 565-585.	0.5	84
17	Bleeding and Thrombosis in High-Risk Renal Transplantation Candidates Using Heparin. Annals of Pharmacotherapy, 2004, 38, 537-543.	0.9	24
18	Lessons in Formulary Management: The Case of Fenoldopam for Radiographic Contrast Material–Induced Nephropathy. Pharmacotherapy, 2004, 24, 819-820.	1.2	0

A SCOTT MATHIS

#	Article	IF	CITATIONS
19	Exaggerated response to heparin in a post-operative renal transplant recipient with lupus anticoagulant undergoing plasmapheresis. Transplantation, 2004, 77, 957.	0.5	6
20	Insights into cyclosporine A-induced atherosclerotic risk in transplant recipients: Macrophage scavenger receptor regulation. Transplantation, 2004, 77, 497-504.	0.5	15
21	EFFECT OF TACROLIMUS ON THE EXPRESSION OF MACROPHAGE SCAVENGER AND NUCLEAR HORMONE RECEPTORS IN THP-1–DERIVED HUMAN MACROPHAGES. Transplantation, 2004, 77, 1281-1287.	0.5	11
22	Drug-related dyslipidemia after renal transplantation. American Journal of Health-System Pharmacy, 2004, 61, 565-85; quiz 586-7.	0.5	21
23	Prescribing Patterns and Outcomes of Enoxaparin for Anticoagulation of Atrial Fibrillation. Pharmacotherapy, 2003, 23, 651-658.	1.2	12
24	Levofloxacin-Associated Achilles Tendon Rupture. Annals of Pharmacotherapy, 2003, 37, 1014-1017.	0.9	23
25	Serum Quinidine Concentrations and Effect on QT Dispersion and Interval. Annals of Pharmacotherapy, 2002, 36, 1156-1161.	0.9	11
26	Probable Case of Torsades de Pointes Induced by Fluconazole. Pharmacotherapy, 2002, 22, 1632-1637.	1.2	37
27	Risk Stratification in Non-ST Segment Elevation Acute Coronary Syndromes with Special Focus on Recent Guidelines. Pharmacotherapy, 2001, 21, 954-987.	1.2	3
28	HYPERCOAGULABLE STATES IN RENAL TRANSPLANT CANDIDATES: IMPACT OF ANTICOAGULATION UPON INCIDENCE OF RENAL ALLOGRAFT THROMBOSIS. Transplantation, 2001, 72, 1073-1078.	0.5	90
29	Newer Antithrombotic Strategies in the Initial Management of Non–ST-Segment Elevation Acute Coronary Syndromes. Annals of Pharmacotherapy, 2000, 34, 208-227.	0.9	3